CDH3 and cancer: There have been some reports on the relationships between renal function and the AUC of CDHP and/or that of 5-FU in patients with cancer [14, 20, 21]; however, these studies did not include patients with severe renal impairment (CLcr ≥ 36.3  mL/min [14], CLcr ≥ 39.0 mL/min [20], and CLcr ≥ 54.0 mL/min [21]).